Rationalisation of Polypharmacy by the Geriatric Consultation Team
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Consultation by the GCT
- Dutch speaking
- 75 years or older
- ...
- Consultation by the GCT
- Dutch speaking
- 75 years or older
- Admitted to a non-geriatric ward
Exclusion Criteria
- End-of-life
- No drugs on admission
- End-of-life
- No drugs on admission
Summary
- Conditions
- Iatrogenic Disease
- Type
- Interventional
- Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 75 years and 125 years
- Gender
- Both males and females
Description
Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric cons...
Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.
Inclusion Criteria
- Consultation by the GCT
- Dutch speaking
- 75 years or older
- ...
- Consultation by the GCT
- Dutch speaking
- 75 years or older
- Admitted to a non-geriatric ward
Exclusion Criteria
- End-of-life
- No drugs on admission
- End-of-life
- No drugs on admission
Tracking Information
- NCT #
- NCT02165618
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Lorenz R Van der Linden, PharmD Universitaire Ziekenhuizen Leuven Principal Investigator: Johan Flamaing, MD, PhD Universitaire Ziekenhuizen Leuven Principal Investigator: Jos Tournoy, MD, PhD Universitaire Ziekenhuizen Leuven
- Lorenz R Van der Linden, PharmD Universitaire Ziekenhuizen Leuven Principal Investigator: Johan Flamaing, MD, PhD Universitaire Ziekenhuizen Leuven Principal Investigator: Jos Tournoy, MD, PhD Universitaire Ziekenhuizen Leuven
Get Well Soon